Haitron "Acquires $13.8 Million Worth of Shares in U.S. Subsidiary"
Haitron announced on the 5th that it will acquire 3,333,333 shares of Exicure, a U.S. nucleic acid therapeutic drug development company, for approximately 13.8 billion KRW.
After acquiring the shares, the ownership stake will be 60.5%. The scheduled date for the stock acquisition is the 14th.
Hot Picks Today
"Auntie, When Will Dried Shredded Squid Return as a Side Dish?"...Once Vanished from Restaurants, Now Making a Comeback
- Monthly Salary Soars 3.7 Times from 8.25 Million Won to 30.59 Million Won... 86 Fair Trade Commission Retirees Join Law Firms Over 10 Years
- [Into the World of AI] Meta's 'Muse' Marks Turning Point for B2C Market Surge... Enhanced Security Vulnerability Warnings
- "You've Earned Your Wealth—Now It's Time to Use It Well"...Seniors Turning to Financial Centers Before Illness Hits [Finance Embracing Seniors] ①
- "V and Go Yoonjung Wear Them Too"... The Transformation of the ‘Grandma Ring’ Captivates Foreigners [K-Holic]
Haitron stated that the purpose of this stock acquisition is a "paid-in capital increase for business expansion."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
